News

Roche obtains FDA 510(k) Approval for Cobas

Roche-3

Roche’s cobas MRSA/SA Test has received 510(k) approval from the US Food and Drug Administration (FDA) for the early and simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) directly from nasal specimens.
The test can detect both organisms from a single specimen, offering accurate results to control MRSA/SA infections, noted Roche.
Roche Molecular Diagnostics head Paul Brown said: “Healthcare-associated infections continue to be a leading cause of mortality in US medical settings.
“With the addition of the cobas MRSA/SA Test to our expanding menu of tests for the cobas 4800 System, Roche offers laboratories and clinicians a highly efficient molecular solution to aid in the overall management and prevention of healthcare-associated infections, leading to lower costs for hospitals and optimal patient care.”
The cobas MRSA/SA Test is a polymerase chain reaction (PCR)-based assay, which runs on the automated cobas 4800 System. It provides simplified workflow available with a simple de-cap and loading of the primary sample vial onto the cobas 4800 System.
The cobas 4800 System is said to provide walk-away automation of nucleic acid purification, PCR set-up and real-time PCR amplification and detection, which will allow laboratories to achieve maximum efficiency.
The expanding system menu currently available in the US includes cobas CT/NG Test (chlamydia/gonorrhea), cobas HPV Test, cobas BRAF V600 Mutation Test and cobas EGFR Mutation Test.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top